These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25988960)

  • 1. Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.
    Zhu Q; Yu Z; Kabashima T; Yin S; Dragusha S; El-Mahdy AF; Ejupi V; Shibata T; Kai M
    Sci Rep; 2015 May; 5():10323. PubMed ID: 25988960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
    Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
    Mammano F; Trouplin V; Zennou V; Clavel F
    J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.
    Rodés B; Poveda E; Soriano V
    J Clin Microbiol; 2002 Nov; 40(11):4313-6. PubMed ID: 12409418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
    Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
    J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
    Magiorkinis E; Paraskevis D; Detsika MG; Lu L; Magiorkinis G; Lazanas M; Imbrechts S; Van Laethem K; Vandamme AM; Pilot-Matias T; Molla A; Camacho RJ; Hatzakis A
    AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1223-9. PubMed ID: 21417947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.
    Descamps D; Apetrei C; Collin G; Damond F; Simon F; Brun-Vézinet F
    AIDS; 1998 Jun; 12(9):1109-11. PubMed ID: 9662212
    [No Abstract]   [Full Text] [Related]  

  • 15. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
    Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
    J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
    Martinez-Picado J; Savara AV; Shi L; Sutton L; D'Aquila RT
    Virology; 2000 Sep; 275(2):318-22. PubMed ID: 10998332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.
    Watkins T; Resch W; Irlbeck D; Swanstrom R
    Antimicrob Agents Chemother; 2003 Feb; 47(2):759-69. PubMed ID: 12543689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.